You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-5 of 5 results found

T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a T-cell receptor (TCR) that confers high-avidity recognition of the HPV-specific oncoprotein E6. The TCR may be used in an adoptive cell therapy approach utilizing genetically engineered lymphocytes to treat HPV-positive malignancies.
  • Therapeutics

Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy

Researchers at the National Cancer Institute (NCI) developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The NCI seeks partners for co-development or licensees for commercialization of novel immunoassays for determining or predicting patient response to cancer therapy.
  • Diagnostics

T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a T-cell receptor (TCR) that confers high-avidity recognition of the HPV-specific oncoprotein E7. The TCR may be used in an adoptive cell therapy approach utilizing genetically engineered lymphocytes to treat HPV-positive malignancies.
  • Therapeutics

Methods of analyzing virus-derived therapeutics

Researchers at the National Cancer Institute’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies, for which the NCI seeks licensees or co-development collaborations.
  • Diagnostics